This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    radiotherapy ARTFORCE | Head and Neck Cancer | Groningen, Netherlands
Previous Study | Return to List | Next Study

Adaptive Radiation Treatment for Head and Neck Cancer (ARTFORCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01504815
Recruitment Status : Active, not recruiting
First Posted : January 5, 2012
Last Update Posted : July 6, 2023
Sponsor:
Collaborators:
Karolinska Institutet
Maastricht Radiation Oncology
Institut Catala de Salut
The Christie NHS Foundation Trust
Gustave Roussy, Cancer Campus, Grand Paris
UMC Utrecht
European Union
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This Phase III trial aims to:

Explore the impact of pre-treatment information and radiation dose redistribution on locoregional control in patients with locally advanced SCCHN.

The dose to the primary tumor with margins, based upon PET and CT information, will be inhomogeneously increased to a tumor dose between 70 and 84 Gy with decreasing dose towards the edges of the irradiated area.

To determine the toxicity of combined modality treatment (cisplatin) with standard dose distribution versus combined modality treatment (cisplatin) with adaptive inhomogeneous radiation dose distribution.


Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: cisplatinum Radiation: Conventional radiotherapy Radiation: Adaptive radiotherapy Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 268 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Randomized Study With Cisplatinum and Conventional or Adaptive High Dose Radiotherapy for Advanced Head and Neck Cancer
Study Start Date : March 2012
Estimated Primary Completion Date : November 2023
Estimated Study Completion Date : September 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Cisplatinum + conventional RT
Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
 Drug: cisplatinum
i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy

Radiation: Conventional radiotherapy
conventional radiotherapy, 70Gy in 7 weeks
Experimental: Cisplatinum + adaptive high dose RT
Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
 Drug: cisplatinum
i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy

Radiation: Adaptive radiotherapy
adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. locoregional recurrence-free survival [ Time Frame: 2 years ]
  2. number of patients with grade 3 toxicity or more [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Quality of Life assessment [ Time Frame: 2 years ]
  2. swallowing preservation [ Time Frame: 1 year ]
    Tube feeding dependency at one year

  3. progression free survival [ Time Frame: 2 years ]
  4. overall survival [ Time Frame: 2 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • biopsy-confirmed squamous cell carcinoma of the oropharynx, oral cavity or hypopharynx
  • stage III/IV, T3-4, Nx M0
  • < 70 yrs
  • glomerular filtration rate (GFR) >60
  • WHO 0-1
  • no previous malignancies except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
  • adequate bone marrow function, adequate hepatic function,informed consent
  • >18 years

Exclusion Criteria:

  • expected failure from follow-up
  • previous malignancies except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
  • expected inability to complete either one of the treatment arms
  • pregnancy or lactation
  • patients (m/f) with reproductive potential not implementing adequate contraceptive measures
  • prior surgery, radiotherapy or chemotherapy for this tumor
  • contraindications or serious concomitant diseases preventing the safe administration of chemotherapy and/or radiotherapy or are likely to interfere with the study assessments
  • known active symptomatic fungal, bacterial and/or viral infections including HIV
  • concomitant (or with 4 weeks before randomisation) administration of any other experimental drug
  • concurrent treatment with any other anti-cancer therapy
  • prior treatment with one or more of the active compounds
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01504815


Locations
Layout table for location information
France
Gustave Roussy Cancer Institute
Villejuif, France, 94800
Netherlands
Netherlands Cancer Institute
Amsterdam, Netherlands, 1066CX
Universitair Medisch Centrum Groningen
Groningen, Netherlands, 9713 GZ
Maastro Clinic
Maastricht, Netherlands, NL-6229 ET
Erasmus Medical Centre
Rotterdam, Netherlands, 3075 EA
University Medical Centre Utrecht
Utrecht, Netherlands, NL-3508GA
Spain
University Hospital Vall d'Hebron
Barcelona, Spain, 08035
Sweden
Karolinska Institute
Stockholm, Sweden, 17177
United Kingdom
Christie Hospital NHS Trust
Manchester, United Kingdom, M20 5BX
Sponsors and Collaborators
The Netherlands Cancer Institute
Karolinska Institutet
Maastricht Radiation Oncology
Institut Catala de Salut
The Christie NHS Foundation Trust
Gustave Roussy, Cancer Campus, Grand Paris
UMC Utrecht
European Union
Investigators
Layout table for investigator information
Principal Investigator: Olga Hamming-Vrieze, MD The Netherlands Cancer Institute
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute
ClinicalTrials.gov Identifier: NCT01504815    
Other Study ID Numbers: M11ART
First Posted: January 5, 2012    Key Record Dates
Last Update Posted: July 6, 2023
Last Verified: July 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Netherlands Cancer Institute:
advanced head and neck cancer
adaptive radiotherapy
cisplatinum
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Cisplatin
Antineoplastic Agents